News archive
Showing 644 results
September 2012
-
Media ReleaseNovartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic communityThe initiative aims to help close diagnosis gap for Hispanic Americans by providing in-language information and resources focused on Alzheimer’s diseaseThe company will work with Univision to help…
-
Media ReleaseNovartis Pharmaceuticals Corporation emprende una campaña de educación de la comunidad hispana de EE. UU. sobre la enfermedad de Alzheimer
-
Media ReleaseNovartis Pharmaceuticals Corporation embarks on Alzheimer’s disease educational effort for the U.S. Hispanic community
-
Media ReleaseFDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis-Tobramycin inhalation powder (TIP) recommended for management of cystic fibrosis (CF) patients six years and older with P. aeruginosa bacteria in their lungs-P. aeruginosa (Pa) is the leading cause…
-
Media ReleaseFDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease-- Approval based on efficacy and safety demonstrated in long-term study comparing 13.3 mg/24 h to 9.5 mg/24 h in declining mild to moderate Alzheimer's patients-- New higher dose of Exelon Patch…
-
Media ReleaseHigher dose of Novartis drug Exelon® Patch approved by FDA for patients with mild to moderate Alzheimer's disease
June 2012
-
Media ReleaseNPC Statement on Comments Made in Media Coverage of Paycheck Fairness ActNovartis Pharmaceuticals Corporation (NPC) is aware of the recent Democratic Steering and Policy Committee session in the U.S. House of Representatives to discuss the Paycheck Fairness Act and…
-
Media ReleaseNPC Statement on Comments Made in Media Coverage of Paycheck Fairness Act
May 2012
-
Media ReleaseTwo new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients• Data from FREEDOMS study show Gilenya reduced relapses in patients who discontinued another MS therapy due to side effects or inadequate efficacy• Analyses of five clinical studies show Gilenya,…
-
Media ReleaseTwo new analyses reinforce consistent efficacy of Novartis therapy Gilenya across wide range of relapsing MS patients
-
Media ReleaseTV host Phil Keoghan and professional women cyclists join Novartis to raise awareness of multiple sclerosis- "Together in MS" partners professional cycling team members with people living with MS for Bike MS rides on tandem bicycles across the country- Phil Keoghan, MS advocate and TV host, rides tandem…